VivoSeq
Nephrology

Renal Replacement Therapy

0

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Renal Replacement Therapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Bayer, Haisco Pharmaceutical Group Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

79/100

Attrition Rate

12/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

0 programs

PreclinicalHaisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

25

clinical trials

Completed11 · 44%
Unknown status7 · 28%
Recruiting2 · 8%
Terminated2 · 8%
Not yet recruiting2 · 8%
Withdrawn1 · 4%

Clinical Trials

Trial Activity

25 trials

Registry of Pre-mixed Solutions in Critically Ill Patients on the Continuous Renal Replacement Therapy
Recruiting·VVantive Health LLC·N/A·NCT06983509·220 enrolled
A Protocol Based-Furosemide Stress Test to Evaluate Renal Recovery During Continuous Renal Replacement Therapy
Recruiting·—·Phase 4·NCT06229990·80 enrolled
Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU)
Not yet recruiting·ZZhujiang Hospital·Phase 2·NCT07469072·92 enrolled
Prospective Analysis of Arteriovenous Access Use in Continuous Renal Replacement Therapy, a Feasibility Project
Not yet recruiting·EEast Carolina University·Preclinical·NCT07447128·50 enrolled
Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis")
Completed·Bayer logoBayer·Phase 1·NCT04510987·48 enrolled
Investigating Different Anticoagulants for Renal Replacement Therapy
Completed·UUniversity Hospital Muenster·Phase 4·NCT02669589·638 enrolled
Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients
Completed·MMedical University of Vienna·Phase 3·NCT02007603·16 enrolled
Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)
Completed·HHospital Universitari de Bellvitge·N/A·NCT04033029·20 enrolled
Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy
Completed·UUniversity Hospital, Toulouse·Phase 4·NCT00703144·10 enrolled
Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy
Completed·KKyungpook National University Hospital·Phase 4·NCT02478242·60 enrolled
The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy
Completed·YYonsei University·Phase 4·NCT01761994·66 enrolled
Furosemide Stress Test Guiding Initiation of Renal Replacement Therapy
Completed·—·N/A·NCT02730117·118 enrolled
Creatinine Clearance as a Predictor of Successful Withdrawl of Continuous Renal Replacement Therapy in Intensive Care
Completed·—·N/A·NCT04375358·64 enrolled
Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement Therapy
Completed·HHartford Hospital·Phase 1·NCT05373615·14 enrolled
Citrate Anticoagulation in Renal Replacement Therapy: Impact of a High Post-filter Calcium Target on Efficacy
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05814341·108 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)